NCT01621256View on ClinicalTrials.gov

Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 18, 2018

Study Completion Date

October 30, 2018

Conditions
Hearing LossDeafnessHearing Loss, SensorineuralHearing DisordersEar Diseases
Interventions
DRUG

Ancrod

Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections

DRUG

Saline solution

Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections

Trial Locations (7)

Unknown

Site CZ, Hradec Králové

Site CZ, Prague

Site D, Göttingen

Site D, Hamburg

Site D, Hanover

Site D, Landsberg am Lech

Site D, München

All Listed Sponsors
collaborator

ClinSupport GmbH

INDUSTRY

collaborator

MWI Medizinisches Wirtschaftsinstitut GmbH

UNKNOWN

collaborator

ProjectPharm s.r.o.

UNKNOWN

collaborator

LCR Leading Clinical Research s.r.o.

UNKNOWN

collaborator

X-act Cologne Clinical Research GmbH

INDUSTRY

lead

Nordmark Arzneimittel GmbH & Co. KG

INDUSTRY

NCT01621256 - Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss | Biotech Hunter | Biotech Hunter